Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Galenea and Otsuka extend and expand schizophrenia research and development collaboration

Oct. 8, 2008

Recent Toray and Xenon patents disclose novel analgesic agents

Oct. 8, 2008

DSMB recommends continuation of BioMS Medical's MAESTRO-03 trial of dirucotide in MS

Oct. 7, 2008

deCODE files IND for DG-071 for Alzheimer's disease and other cognitive disorders

Oct. 7, 2008

TorreyPines reports successful end-of-phase II meeting with FDA for tezampanel

Oct. 6, 2008

Recent GSK patent describes new analgesic agents

Oct. 6, 2008

Galectin-3 as potential therapeutic target in post-ischemic functional recovery

Oct. 6, 2008

Merck & Co. identifies a novel bradykinin B1 antagonist

Oct. 3, 2008

Phase II/III study results reported for Arocyte for injection in Japan

Oct. 3, 2008

Pharmaleads advances its lead pain compound, PL-37, into phase I trials

Oct. 3, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...